clinical trial · NCT07454382
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Multiple MyelomaElranatamab-bcmmCyclophosphamide
brief summary
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
started
Feb 27, 2026
primary completion
Aug 27, 2029
completion
Aug 27, 2029
last updated
Mar 6, 2026
official title
Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol